News
Media contacts:
Sandra Wirsching | s.wirsching@biocom.de | +49-30-264 921-63
Clément Robijns | c.robijns@biocom.de | +49-30-264 921-58
CARB-X announced the investment of first grants to two German research teams from the German Helmholtz…
Researchers from the Helmholtz Centre for Infection Research (HZI) and the Lead Discovery Center GmbH (LDC)…
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) team could receive up to US$6.31 million if all…
Single intravenous dose Phase 1 study in healthy volunteers showed that EBL-1003 (apramycin) was safe and…
High-level global leaders group will advocate for urgent action to combat antimicrobial resistance across all sectors…
The Global AMR R&D Hub publishes its first report “The state of public and philanthropic investments…
The BEAM Alliance recently worked with Global Cause on the 2020 Antimicrobial Resistance campaign. The content…
BV100 is being developed for the treatment of serious hospital infections caused by Carbapenem resistant Acinetobacter baumannii…
CARB-X announced today it is awarding up to US$2.62 million to Polyphor AG (SIX:POLN), headquartered in…
On 6 October, the MEP interest group on AMR released an official letter to the EU…
CARB-X announced today it is awarding up to US$7.51 million to GlaxoSmithKline (NYSE: GSK), to develop…
With around 450 attendees, the five-day digital conference particularly focused on market conditions and financing. SMEs…
Swiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two…
British diagnostics company FluoretiQ Ltd was selected as start-up pitch winner during the 4th annual AMR…
BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics…
Dr Manica Balasegaram, GARDP Executive Director, spoke at the opening of BIOCOM’s 4th AMR Conference on…
Antinfectives specialist AiCuris GmbH will launch the “AiCubator”, a new way to collaborate in anti-infectives and…
Evotec is the first pharmaceutical R&D company based in Germany in the CARB-X portfolio CARB-X announced…
Bachem and Jitsubo CO., LTD. recently announced the signature of an exclusive Licensing Agreement for Jitsubo’s…
A remarkable 2-part PBS News Hour story exclusively dedicated to AMR The antibiotics industry has suffered…
A remarkable 2-part PBS News Hour story exclusively dedicated to AMR COVID-19 can be accompanied by…
CARB-X is funding Spanish biotech Vaxdyn to develop a new vaccine to prevent infections that cause…
The AMR Action Fund expects to invest more than US$1 billion in smaller biotech companies and…
With a unique approach, Eligo engineers natural predators of bacteria to deliver CRISPR systems that kill…
Big Pharma exited from the antibiotics space one by one – and now they may be…
Access to surveillance data crucial to tackling infectious diseases Wellcome Trust has partnered with Pfizer Inc.…
CARB-X is awarding up to US$3.83 million to The University of Queensland’s Institute for Molecular Bioscience,…
CARB-X will invest up to $3m into India-based diagnostics company Module Innovations whichis developing a rapid…
The June issue of ACS Infectious Diseases is a special issue on antibiotics featuring all major…
GARD is looking for a new Board member with high-level executive experience and strategy setting in…
Until 31 July 2020 companies developing new treatments to combat AMR are invited to submit proposals.…
CARB-X is investing up to $11m into US-based Microbion to develop its inhaled drug pravibismane to…
CARB-X funds US-based Facile Therapeutics to further develop a new oral drug that would disable toxins…
CARB-X will support US-based Day Zero Diagnostics with $6.2M. The company combines whole-genome sequencing and machine…
Until 25th August companies, institutions and individuals are invited to submit data on their products that…
Faced with antibiotic resistance, pharmaceuticals and governments could be doing much more, warns Manica Balasegaram, Executive Director of GARDP,…
The Global AMR R&D Hub’s Dynamic Dashboard continuously collects and presents information on AMR R&D investments,…
COMBINE will support the coordination of the Innovative Medicines Initiative (IMI) Antimicrobial Resistance (AMR) Accelerator Programme…
For the first time, scientists from Jena succeeded to cultivate and functionally characterize a total of…
A new EU report sees only slow progress in the fight against AMR. The BEAM Alliance…
A drug combo breaking antibiotic resistance of Gram-negative priority pathogens has been selected under the ENABLE…
Despite challenging markets new players are entering the field to advance drug development in the fight…
Antibiotic developers struggle with uncertain market conditions, weak reimbursement schemes and low turnover once a drug…
Swiss biotech company BioVersys AG has received a €8m grant by US-based non-profit organisation CARB-X to…
Swiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action…
In 2019, a new AMR accelerator kicked off under the aegis of the Innovative Medicines Initiative…
UK–based biotech company Procarta Biosystems has been funded by CARB-X to develop a new class of…
India has joined the Global AMR R&D Hub as a new Member. This expands the global…
Swiss researchers from Zurich and Basel have discovered that resistance in intestinal bacteria can spread even…
WHO has published target product profiles for diagnostics against antibacterial resistance identified as priorities. Until 29th…
Erin Duffy, former CSO of US biotech company Melinta Therapeutics, replaces Karen Gallant as CARB-X‘s Chief…
CARB-X has recently funded several vaccines projects to fight AMR-related infections developed by US-based SutroVax and…
The WHO has developed several draft target products profiles (TPPs) and is seeking feedback from AMR…
Nabriva Therapeutics plc has got the go from the FDA to market its pleuromutilin antibiotic Xenleta…
Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel…
